Skip to main content
. 2021 Jul 17;11:100108. doi: 10.1016/j.metop.2021.100108

Table 2.

Dyslipidemia by comorbidity with hypertension, diabetes, and medical profiles of patients (n = 372).

Variable Frequency (%) TC ≥ 240 mg/dL (6.21 mmol/) TG ≥ 200 mg/dL (2.26 mmol/) LDL-C ≥ 160 mg/dL (4.14 mmol/) HDL-C < 40 mg/dL (1.03 mmol/L)
Classifications of Hypertensive patients Normal 69(18.5) 4(5.8) 3(4.3) 2(2.9) 5(7.2)
Stage 1 77(20.7) 9(11,7) 18(23.4) 7(9.1) 25(32.5)
Stage 2 127(34.1) 35(27.6) 41(32.3) 25(19.7) 49(38.6)
Stage 3 99(26.6) 25(25.3) 29(29.3) 26(26.3) 36(36.4)
Total 372 73(19.6) 91(24.5) 60(16.1) 115(30.9)
Duration of hypertension <5 84(22.6) 10(11.9) 16(19.0) 8(9.5) 21(25)
5–9 73(19.6) 11(15.1) 15(20.5) 11(15.1) 18(24.7)
10–14 56(15.1) 6(10.7) 12(21.4) 6(10.7) 17(30.4)
15–20 68(18.3) 16(23.5) 18(26.5) 20(29.4) 29(42.6)
>20 91(24.5) 30(32.9) 30(32.9) 15(27.5) 30(32.9)
Total 372 73(19.6) 91(24.5) 60(16.1) 115(30.9)
Diabetes mellitus Yes 87(23.4) 39(44.8) 41(47.1) 29(33.3) 42(48.3)
No 285(76.6) 34(11.9) 50(17.5) 31(10.9) 73(25.6)
Total 372 73(19.6) 91(24.5) 60(16.1) 115(30.9)
BMI Underweight 36(9.7) 2(5.6) 4(11.1) 2(5.6) 5(13.9)
Normal 122(32.8) 8(6.6) 11(9.0) 6(4.9) 18(14.8)
Overweight 121(32.5) 27(22.3) 34(28.1) 22(18.2) 39(32.2)
Obesity 93(25.0) 36(38.7) 42(45.2) 30(32.3) 53(56.9)
Total 372 73(19.6) 91(24.5) 60(16.1) 115(30.9)
Family history of lipid Yes 102(27.4) 30(29.4) 55(53.9) 38(37.3) 52(50.9)
No 270(72.6) 43(15.9) 36(13.3) 22(8.1) 63(23.3)
Total 372 73(19.6) 91(24.5) 60(16.1) 115(30.9)
Overall prevalence of Dyslipidemia Yes 180(48.4)
No 192(51.6)